A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

Phase 2

Completed

• Conditions: SARS-CoV-2 Infection
• Interventions: Drug: BTL-TML-COVID; Drug: Placebo

• Registration Number: NCT04522830
• Lead Sponsor: Beech Tree Labs, Inc.

Brief Summary

Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-30
• Study First Submitted: 2020-08-18
• Study First Submitted QC: 2020-08-20
• Study First Posted: 2020-08-21
• Primary Completion: 2021-02-28
• Study Completion: 2021-02-28
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-09
• Last Update Posted: 2021-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• 40 years of age or older
• Provide written informed consent
• Have a SARS-COV-19 diagnostic test with positive results

Exclusion Criteria

• Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
• Subjects currently hospitalized
• Subjects who have received a COVID vaccination
• Subjects with a diagnosis of immunodeficiency

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BTL-TML-COVID	BTL-TML-COVID	BTL-TML-COVID
Placebo	Placebo	Placebo

Primary Outcome Measures

Name	Time	Method
Mean duration and severity of disease	Two days	Change from baseline in the physical component summary of the short form-36 Quality of Life Instrument

Secondary Outcome Measures

Name	Time	Method
Incidence/Safety of Adverse Events	Baseline through 10 days	AEs will be assessed by the investigator as to severity, duration and relationship to treatment

Trial Locations

Locations (1)

Intermountain Clinical Reserach; 🇺🇸 Draper, Utah, United States